OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dadu on Treatment Approaches in Medullary Thyroid Cancer

December 22nd 2016

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches in medullary thyroid cancer.

Dr. Perales on the PROGRESS II Trial in Hematologic Malignancies

December 22nd 2016

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, provides an overview of the PROGRESS II trial, which was conducted for patients with hematologic malignancies.

Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLL

December 22nd 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses the results of a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia whose disease had progressed after treatment with either ibrutinib or idelalisib.

Dr. Takahashi on Biomarker That Predicts Development of Therapy-Related Leukemia

December 21st 2016

Koichi Takahashi, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study exploring a potential biomarker for patients likely to develop therapy-related leukemia.

Dr. Goy on Rituximab Maintenance Therapy for Patients With MCL

December 21st 2016

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses phase III results of a study exploring rituximab as maintenance therapy after autologous stem cell transplantation in younger patients with mantle cell lymphoma.

Dr. Kolibaba on Entospletinib Activity in Mantle Cell Lymphoma

December 21st 2016

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses a study of entospletinib in the treatment of patients with mantle cell lymphoma.

Dr. Klopp on Goals With IMRT in Gynecological Cancers

December 20th 2016

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the next steps to take with pelvic intensity-modulated radiation therapy for patients with gynecological cancers.

Dr. Pavlick on Immunotherapy Clinical Trials in Basal and Squamous Cell Carcinomas

December 20th 2016

Anna C. Pavlick, DO, medical oncologist, NYU Langone School of Medicine, discusses ongoing clinical trials exploring treatment with immunotherapy in patients with basal cell carcinoma as well as squamous cell carcinoma.

Dr. Venook on Important Factors for Treating Patients With CRC

December 20th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses important factors for oncologists to consider when treating patients with colorectal cancer.

Dr. de Souza on Next Steps for Immunotherapy in Head and Neck Cancer

December 20th 2016

Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.

Dr. Luke on Challenges With Immunotherapy in Melanoma

December 20th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses some of the challenges that oncologists may face when administering immunotherapy agents to patients with melanoma.

Dr. Goy on Changing Treatment Landscape of Mantle Cell Lymphoma

December 20th 2016

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses how the treatment landscape of mantle cell lymphoma is evolving.

Dr. Fedyanin on Future Treatment Landscape of CRC

December 20th 2016

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).

Dr. Birrer on FDA Approval of Rucaparib in Ovarian Cancer

December 19th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the FDA approval of rucaparib for as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.

Dr. Marshall on Next Steps Following Y-90 in Liver-Metastatic CRC

December 17th 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).

Dr. Twardowski on Steps Toward Optimal Sequencing for mCRPC Therapies

December 17th 2016

Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, discusses the necessary steps toward determining optimal sequencing of treatments for patients with metastatic castration-resistant prostate cancer.

Stefani Spranger on Checkpoint Blockade Therapies in Melanoma

December 16th 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses immune checkpoint blockade therapies that are currently being used to treat patients with melanoma.

Dr. Bekaii-Saab on the Expansion of Treatment Options in Colorectal Cancer

December 16th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the recent expansion of treatment options available for patients with colorectal cancer.

Dr. Hamid on Promising Phase III Trials in Melanoma

December 16th 2016

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses 2 exciting, ongoing phase III randomized trials in melanoma.

Dr. Burtness on the Use of Immunotherapy After Chemoradiation in Head and Neck Cancer

December 15th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the use of immunotherapy in patients with head and neck cancer who have residual disease following treatment with chemotherapy and radiation.